ソース:[1] Gilead Sciences advances HIV prevention with US partnership (https://www.pharmaceutical-technology.com/new ...)[2] Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low and Lower Middle Income Countries (https://vertexaisearch.cloud.google.com/groun ...)[3] Gilead Announces Partnership With PEPFAR to Deliver Twice Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low and Lower Middle Income Countries (https://vertexaisearch.cloud.google.com/groun ...)